home / stock / lxrx / lxrx news

LXRX News and Press, Lexicon Pharmaceuticals Inc. From 08/05/22

Stock Information
Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com
Menu
LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...
LXRX - Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “ Common Stock ”)...
LXRX - Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2022 Results - Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2022 Earnings Conference Call August 2, 2022 17:00 ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz - Sen...

LXRX - Lexicon Pharmaceuticals GAAP EPS of -$0.16 in-line, revenue of $0.04M misses by $0.06M

Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.04M (-80.0% Y/Y) misses by $0.06M . “We received acceptance last week of our New Drug Application (NDA) for sotagliflozin for the treatment of heart failure ...

LXRX - Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neurop...
LXRX - Lexicon Pharmaceuticals Q2 Earnings Preview

Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, after market close. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $0.1M (-50.0% Y/Y). For further details see: Lexicon Pharm...

LXRX - Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET...

LXRX - ATHX and REX among mid-day movers

Gainers: REX American Resources ( REX ) +195% . SQL Technologies ( SKYX ) +64% . Athersys ( ATHX ) +66% . JAKKS Pacific ( JAKK ) +34% . Aridis Pharmaceuticals ( ARDS ) +33% . Better Therapeutics ( BTTX ) +32% . Co...
LXRX - Better Therapeutics, GeoVax top healthcare gainers; Community Health, Bausch lead losers' pack

Gainers: Better Therapeutics BTTX +43% . GeoVax Labs ( GOVX ) +22% . Aridis Pharmaceuticals ( ARDS ) +19% . Comera Life Sciences ( CMRA ) +13% . Gracell Biotechnologies ( GRCL ) +13% . Losers: Community Health Systems ( CYH ...

LXRX - Lexicon Pharma slumps on pricing $85M stock offering and concurrent private placement

Lexicon Pharmaceuticals ( NASDAQ: LXRX ) priced its earlier announced underwritten public offering of 16.8M shares, par value $0.001, at $2.5/share. Gross proceeds are expected to be ~$42.1M. Underwriters granted 30-day option to purchase up to an additional 2.53M...

LXRX - Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the ...
Previous 10 Next 10